Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.58 |
| ▸ | CTSK | P43235 | 4/20 | 0.58 |
| ▸ | CTSS | P25774 | 3/20 | 0.58 |
| ▸ | CTSB | P07858 | 3/20 | 0.58 |
| ▸ | ECE1 | P42892 | 2/20 | 0.57 |
| ▸ | MME | P08473 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 2/20 | 0.53 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 3/20 | 0.52 |
| ▸ | CASP1 | P29466 | 2/20 | 0.52 |
| ▸ | CASP7 | P55210 | 2/20 | 0.52 |
| ▸ | CASP6 | P55212 | 2/20 | 0.52 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.52 |
| ▸ | CASP9 | P55211 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopropylamine SCHEMBL10558459 | 0.96 | CTSL (0.59) | CTSLCTSKCTSSCTSBECE1 | |
| SCHEMBL8671882 | 0.94 | CTSL (0.63) | CTSLCTSKCTSSCTSBECE1 | |
| SCHEMBL2978398 | 0.94 | CTSL (0.63) | CTSLCTSKCTSSCTSBECE1 | |
| SCHEMBL220569 | 0.94 | CTSL (0.63) | CTSLCTSKCTSSCTSBECE1 | |
| SCHEMBL1287168 | 0.94 | CTSL (0.63) | CTSLCTSKCTSSCTSBECE1 | |
| Valine SCHEMBL5917142 | 0.92 | CTSL (0.56) | CTSLCTSKCTSSCTSBECE1 | |
| Glycine SCHEMBL8365362 | 0.90 | CTSL (0.57) | CTSLCTSKCTSSCTSBECE1 | |
| SCHEMBL6272667 | 0.89 | ECE1 (0.64) | CTSLCTSKCTSSCTSBECE1 | |
| SCHEMBL7378851 | 0.89 | ECE1 (0.64) | CTSLCTSKCTSSCTSBECE1 | |
| SCHEMBL20869899 | 0.89 | CTSL (0.57) | CTSLCTSKCTSSCTSBECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7270801-B2 | Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof | CYTOVIA, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1026988-A4 | NOVEL FLUORESCENT REPORTER MOLECULES AND THEIR APPLICATIONS INCLUDING ASSAYS FOR CASPASES | CYTOVIA INC (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20040191844-A1 | Novel fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof | CYTOVIA, INC. (US) | 2004-09-30 | — | — | US | disclosed |
| US-6759207-B2 | REPORTER COMPOUND FOR USE IN THE DIAGNOSIS, DETECTION AND TREATMENT OF CANCER | CYTOVIA, INC. | 2004-07-06 | — | — | US | disclosed |
| US-20040009923-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | DOLLE ROLAND E (US) | 2004-01-15 | — | — | US | disclosed |
| US-6576614-B1 | Administering methyl ketones or closed hemiketal derivatives of aspartic acid | VERTEX PHARMACEUTICALS INCORPORATED | 2003-06-10 | — | — | US | disclosed |
| US-20020150885-A1 | Novel fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof | CYTOVIA, INC. | 2002-10-17 | — | — | US | disclosed |
| US-6342611-B1 | BLOCKED RHODAMINE DERIVATIVES | CYTOVIA, INC. | 2002-01-29 | — | — | US | disclosed |
| US-6335429-B1 | COMPOUND INCLUDING SUBSTRATE FOR ENZYME AND RHODAMINE DYE; DRUG SCREENING FOR ANTICARCINOGENIC AGENTS | CYTOVIA, INC. | 2002-01-01 | — | — | US | disclosed |
| EP-0623592-B1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | VERTEX PHARMA (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1026988-A1 | NOVEL FLUORESCENT REPORTER MOLECULES AND THEIR APPLICATIONS INCLUDING ASSAYS FOR CASPASES | Cytovia, Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5985838-A | TREATING INFECTIOUS DISEASE, RESPIRATORY DISEASE, INFLAMMATORY CONDITIONS, IMMUNE-BASED DISEASE, AUTO-IMMUNE DISEASE, BONE DISEASE, AND TUMORS | VERTEX PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1999018856-A1 | NOVEL FLUORESCENT REPORTER MOLECULES AND THEIR APPLICATIONS INCLUDING ASSAYS FOR CASPASES | CYTOVIA, INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| EP-0623592-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | STERLING WINTHROP INC. (US) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009923-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | IL1B, IL1A, IL1RN | CTSL 25/4885CTSK 126/4885CTSS 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.